Sulphated vinyl polymer in composition for treating retroviral infections
AssigneesStichting Rega VZW, Richter Gedeon Vegyeszeti Gyar Rt.
InventorsMasanori Baba, Erik D. A. De Clercq, Sandor Gorog, Miklos Low, Miklos Nagy, Sandorne Gyorgyi
Life of this patent
Estimating the term…
Abstract
Sulphated vinyl polymers such as sulphated polyvinylalcohol, sulphated copolymers of (meth)acrylic acid and vinylalcohol, and pharmaceutically acceptable salts thereof, have an antiviral effect against human immunodeficiency virus and may therefore be used as a therapeutic agent for treating retrovirus infections like AIDS and AIDS-related diseases. Their antiviral activity is apparently based on inhibition of virus adsorption; their inhibitory effect on giant cell formation is stronger than that of dextran sulphate.
Claims7
A pharmaceutical composition in unit dosage form for treating of immunodeficiency disease causally connected to human immunodeficiency virus, comprising at least one pharmaceutically acceptable excipient and a quantity of a sulfated vinyl polymer active ingredient selected from the group consisting of sulfated polyvinylalcohol and sulfated copolymers of (meth)acrylic acid and vinylalcohol, wherein said sulfated vinyl polymer further has a sulfation degree between 50 and 60%, in an amount which upon administration of one or more unit doses thereof establishes a blood plasma concentration of 0.8-4 .mu.g/ml, effective to treat said immunodeficiency disease, and to demonstrate improved effectiveness against HIV-1 and HIV-2 virus, in a patient to which one or more unit doses are administered.
Dependencies are inferred from the claim text.